Microbot Medical Inc. reported significant financial challenges in its latest 10-K filing for the fiscal year ending December 31, 2025. The company has not recognized any revenues to date and continues to incur substantial operating losses, totaling approximately $104.1 million since its inception. For the year ended December 31, 2025, Microbot's net working capital increased to approximately $76.4 million, up from $3.4 million in 2024, primarily due to successful capital raises. The company raised approximately $168.3 million through various financing activities, including equity offerings and grants from the Israeli Innovation Authority.
In terms of operational developments, Microbot has focused on the commercialization of its LIBERTY® Endovascular Robotic Surgical System, which received FDA clearance in September 2025. The company has initiated a limited market release of LIBERTY® in select high-demand regions and plans for a full market launch at the Society of Interventional Radiology conference in April 2026. Additionally, Microbot has entered into a collaboration with Emory University to explore the integration of LIBERTY® with imaging systems for autonomous robotic procedures.
The company has also made strategic changes, including the acquisition of assets from Nitiloop Ltd. in October 2022, which expanded its product portfolio with intraluminal revascularization devices. As of March 2026, Microbot employed 43 individuals, with plans to increase its U.S.-based commercial team to support its growth strategy. The company is also pursuing ISO 13485 certification to facilitate its entry into European markets, anticipating CE Mark approval by the second half of 2026.
Despite these developments, Microbot faces numerous risks, including the need for additional capital to sustain operations and the potential impact of geopolitical tensions in Israel on its business. The company has acknowledged that it may not achieve profitability and could be forced to curtail its commercialization efforts if it fails to secure necessary funding. Furthermore, the success of the LIBERTY® system hinges on market acceptance and the ability to demonstrate its safety and effectiveness compared to existing technologies.
Looking ahead, Microbot's management remains cautious, emphasizing the uncertainty surrounding its future revenue generation and the ongoing need for funding to support its commercialization and research efforts. The company is committed to expanding its technology platforms and enhancing its product offerings, but it recognizes the inherent risks associated with the medical device industry and the challenges of navigating regulatory landscapes.
About Microbot Medical Inc.
Microbot Medical Inc. develops minimally invasive robotic surgical devices, focusing on endovascular procedures. Its flagship LIBERTY system is a disposable, remotely operated robot designed to improve navigation, safety, and access in vascular interventions. The company targets global markets, including the U.S. and Europe, leveraging innovative technology, strategic partnerships, and regulatory approvals to establish its products as standards of care in interventional medicine.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.